Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sheena Taha"'
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-15 (2024)
Abstract Background Harm reduction (HR) is a critical response to the pronounced toxicity deaths being experienced in Canada. HR providers report many benefits of their jobs, but also encounter chronic stress from structural inequities and exposure t
Externí odkaz:
https://doaj.org/article/469c8700d1524bd882863415a7c8a3f0
Autor:
Triti Khorasheh, Caroline Bennett AbuAyyash, Maryam Mallakin, Kate Sellen, Kim Corace, Bernadette Pauly, Daniel Buchman, Michael Hamilton, Nick Boyce, Karen Ng, Carol Strike, Sheena Taha, Heather Manson, Pamela Leece
Publikováno v:
BMC Public Health, Vol 22, Iss 1, Pp 1-14 (2022)
Abstract Background Many communities across North America are coming together to develop comprehensive plans to address and respond to the escalating overdose crisis, largely driven by an increasingly toxic unregulated drug supply. As there is a need
Externí odkaz:
https://doaj.org/article/33f6c9454982429196901689d45cc4d8
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 14, Iss 1, Pp 1-10 (2019)
Abstract Background Canada is facing an urgent challenge to reduce the harms associated with opioids: from January 2016 to December of 2018, more than 11,500 individuals lost their lives due to opioid related harms. This review examines responses to
Externí odkaz:
https://doaj.org/article/bdb4f110fa39422eaa251cd935f8299b
Autor:
Danielle Rice, Kimberly Corace, Dianna Wolfe, Leila Esmaeilisaraji, Alan Michaud, Alicia Grima, Bradley Austin, Reuben Douma, Pauline Barbeau, Claire Butler, Melanie Willows, Patricia A Poulin, Beth A Sproule, Amy Porath, Gary Garber, Sheena Taha, Gord Garner, Becky Skidmore, David Moher, Kednapa Thavorn, Brian Hutton
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0244401 (2020)
BackgroundGuidelines recommend that individuals with opioid use disorder (OUD) receive pharmacological and psychosocial interventions; however, the most appropriate psychosocial intervention is not known. In collaboration with people with lived exper
Externí odkaz:
https://doaj.org/article/e6d86b4f8218476d8c52dee8b1f0289a
Autor:
Lauren A. Paul, Ahmed M. Bayoumi, Cynthia Chen, Elena Kocovska, Brendan T. Smith, Janet M. Raboud, Tara Gomes, Claire Kendall, Laura C. Rosella, Lisa Bitonti‐Bengert, Brian Rush, Melissa Yu, Sheryl Spithoff, Frank Crichlow, Amy Wright, Jase Watford, Jes Besharah, Charlotte Munro, Sheena Taha, Bohdan Nosyk, Carol Strike, Heather Manson, Meldon Kahan, Pamela Leece
Publikováno v:
Addiction. 118:686-697
Although opioid-related harms have reached new heights across North America, the size of the gap in opioid agonist therapy (OAT) delivery for opioid-related health problems is unknown in most jurisdictions. This study sought to characterize the gap i
Autor:
Sheena Taha, Melissa Holowaty, Carol Strike, Pamela Leece, Heather Manson, Sharon E. Straus, Triti Khorasheh, Kimberly Corace, Keith Ahamad, Erin Grennell, Elisabeth Marks, Beata Pach, Ahmed M. Bayoumi
Publikováno v:
BMJ Open
IntroductionIn the context of the opioid crisis in North America, the benefits of evidence-based opioid agonist treatments such as buprenorphine/naloxone have not been optimised due to low uptake. Numerous factors contribute to the underuse of bupren
Autor:
Jayne Caldwell, Carol Strike, Pamela Leece, Heather Manson, Greg Penney, Sue Keller-Olaman, Sheena Taha, Susan Massarella, Michael Parkinson, Rita Henderson, Triti Khorasheh, Nimitha Paul
Publikováno v:
BMJ Open
ObjectivesWe sought to understand the implementation of multifaceted community plans to address opioid-related harms.DesignOur scoping review examined the extent of the literature on community plans to prevent and reduce opioid-related harms, charact
Autor:
Gary Garber, Fatemeh Yazdi, Danielle B. Rice, Kednapa Thavorn, Leila Esmaeilisaraji, Dianna Wolfe, Kimberly Corace, Melanie Willows, David Moher, Brian Hutton, Amy Porath, Sheena Taha, Patricia A. Poulin, Beverley Shea, Becky Skidmore, Beth Sproule
Publikováno v:
BMJ Open
IntroductionThe opioid crisis has resulted in increasing rates of death caused by problematic opioid use. Current clinical guidelines recommend that individuals with persons with opioid use disorder (OUD) receive pharmacological (eg, opioid agonist t